To evaluate systematically the safety and efficacy of intraoperative cell salvage (ICS) in urology.
Results
Fourteen observational studies were identified, with a total of 4 536 patients. ICS was compared with no the blood conservation technique (seven studies), preoperative autologous donation (PAD; five studies) or both (two studies In the non-prostatectomy setting, ATRs amongst patients who underwent ICS were significantly higher or similar in one and two studies, respectively. Tumour recurrence was found to be significantly less common (two studies), similar (eight studies) or not measured (four studies). All six studies reporting complications found no difference in their ICS cohorts. Regarding cost, one study from 1995 found ICS more expensive than PAD, while two more recent studies found ICS to be cheaper than no blood conservation technique. As a result of inter-study heterogeneity, metaanalyses were not possible for recurrence, complications or cost.
Introduction
Intra-operative blood loss remains a challenge in urology. Over time, allogeneic transfusion rates (ATRs) have progressively fallen for many urological procedures, aided by successive waves of new technology, such as minimally invasive surgery and novel operative energy sources [1, 2] ; however, even in high-volume centres, ATRs remain high for the hallmark open oncological procedures of radical nephrectomy (<45% [3] ), cystectomy (<60% [4] ) and prostatectomy (<9% [5] ).
The introduction of well-resourced blood banks has made allogeneic blood transfusion safer. Nevertheless, this practice involves the key challenges of transfusion-transmitted infections, transfusion reactions and potentially poorer oncological outcomes [6] [7] [8] . Additional problems include supply and cost. Blood bank shortages are well reported [9] . A single red blood cell unit costs~US$1000 in Australia and the USA and US$600 in Western Europe [10, 11] . These difficulties are dramatically increased in the developing world [12] . Lastly, as with other malignancies, recent meta-analyses for patients undergoing radical retropubic prostatectomy (RRP), radical nephrectomy or radical cystectomy (RC) have found that allogeneic blood transfusion is associated with worse oncological outcomes [13, 14] . Mechanisms remain poorly understood, and may relate to transfusion-related immunomodulation [15] .
Surgeons have a range of peri-operative blood conservation techniques at their disposal. These include preoperative erythropoietin or iron supplementation, preoperative autologous donation (PAD), acute normovolaemic haemodilution (ANH), restrictive transfusion thresholds and intra-operative cell salvage (ICS); however, each has limitations. Supplements are only applicable for patients with anaemia or iron-deficiency and require multiple healthcare visits for testing, and the efficacies of administration and re-testing are ambiguous [16] . Because of the emergence of transfusion-transmitted infections, particularly HIV, PAD was initially deemed to be the safest blood conservation technique [17] ; however, it similarly requires additional patient visits, 50% of pre-donated units are discarded, it is not costeffective and it is now rarely used [17, 18] . ANH consists of intra-operative collection of patient blood, replacement with colloid or crystalloid to allow haemorrhage of dilute blood, then re-infusion of the collected blood. While cost-effective, it may cause hypotension and is unsuitable for patients with low haematocrit levels [17, 18] . Restrictive thresholds have become commonplace, with clear benefit [19] ; however, these are inappropriate for patients with symptomatic or significant haemorrhage.
The ICS technique represents the safe reinfusion of lost blood. Blood spilled in the surgical field is aspirated with a sterile dual-lumen sucker, with either heparinized saline or citrate added to the second lumen to prevent coagulation. Blood is collected in a reservoir. When desired, these losses are washed with saline and centrifuged to obtain a concentrate with haematocrit of 50-70%. This product is then reinfused, often after passing through a leucocyte depletion filter to remove nucleated cells such as bacteria and tumour cells [20] .
This ICS system elegantly sidesteps many concerns of other blood conservation techniques. It is cost-effective, the risk of horizontal transmission of infection is almost eliminated and supply closely matches demand. ICS has enjoyed enthusiastic uptake and positive results in cardiac, vascular and orthopaedic surgery, where blood loss is often substantial [21] ; however, uptake in urology has been slow because of cost concerns, unclear benefit and potential reinfusion of malignant cells [22] [23] [24] .
To date, no systematic review exists regarding ICS efficacy in urology. The aim of the present review, therefore, was to summarize current data regarding the impact of ICS in urological procedures on ATRs, oncological outcomes, complications and cost. We hypothesized that ICS would be found to reduce ATR and be equivalent or superior in other measures.
Methods

Search Strategy
A systematic search of Cochrane Central Register of Controlled Trials (CENTRAL), Embase and Medline was conducted in August 2017. 'Grey literature' was also searched. The complete free-text search terms, search strategy and list of retrieved full text articles can be found in Appendices S1 and S2. The only limit applied for searches was a publication date prior to 1 August 2017.
Inclusion Criteria
Inclusion criteria were agreed on by all authors. Our method for identifying and evaluating data complied with the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) criteria [25] (Fig. 1) . This included prepublication of our intended analysis on PROSPERO (CRD42017071627). Identified studies were screened by title and abstract, followed by full-text review. Articles then progressed to data extraction, including review of references. Two independent authors performed study screening and data extraction, using a predefined form (Appendix S3). Data extraction was performed twice, to confirm accuracy. The final list of included studies was determined by compliance with the inclusion criteria and with the consensus of all authors.
Study Eligibility
Study eligibility was determined using the patient population, intervention, comparator, outcome and study method [25] . Eligible studies assessed patients undergoing urological surgery, had a cohort treated with ICS, a comparator cohort without such treatment, and reported outcomes on any of ATR, tumour recurrence, complications or cost. Eligible studies were original, published in English, comparative in nature and not a case series or case report. If randomized controlled trials (RCTs) were found and adequate reason existed to include non-randomized studies, they were to be presented separately. If multiple studies with overlapping samples met the inclusion criteria, these were included, with their commonality made clear.
Intended Analyses
A qualitative summary was intended for all data. Quantitative synthesis (meta-analyses) was planned if sufficient similar studies were available, performed as sub-groups by operation type.
Meta-analysis was performed in REVIEW MANAGER software version 5.3 (the Nordic Cochrane Centre, the Cochrane Collaboration, Copenhagen, Denmark). For each study included in the meta-analysis, the number of cases and controls, and outcomes per group were extracted. Fixed effects analysis was used throughout. Forest plots were used to assess publication bias for each meta-analysis.
Bias
The authors did not expect to identify any RCTs. As such, risk of bias was assessed with the Newcastle-Ottawa Scale, in accordance with the Cochrane Handbook [26, 27] . Two reviewers independently assessed each study according to predefined guidelines (Appendix S4). These were informed by the typical demographics and recurrence time frames of patients undergoing RRP [28, 29] , RC [30] and partial nephrectomy (PN) [31] . Disagreements were resolved by consensus. Studies were not excluded on the basis of risk of bias. Publication bias was assessed with funnel plots.
Results
Our search identified 170 studies (1 August 2017). Elimination occurred as a result of irrelevance (51 studies), lack of a comparator group (23 studies), ICS being discussed [17, 42] ) and open PN (one study [43] ). There were no studies on ICS during urological laparoscopic or robot-assisted procedures, nor for other major urological procedures associated with high peri-operative transfusion rates, such as retroperitoneal lymph node dissection.
The ICS technique was compared with PAD [22, [32] [33] [34] [35] 38, 41] , no ICS [17, 36, 37, 39, 40, 42, 43] or no transfusion [32, 34] . Some studies had more than one comparator group. The primary outcomes were ATR (12 studies) and cancer recurrence (10 studies), with secondary outcomes of complications (four studies) and cost (three studies). Notably, overlapping samples were found, with groups of two [38, 41] and three [34, 36, 40] studies representing enlarging RRP sets at the same institutions. These were included and clearly highlighted.
Allogeneic Transfusion Rates
Twelve studies reported ATRs. Compared with cohorts undergoing other blood conservation techniques, ATRs in cohorts undergoing ICS were lower (two studies [33, 39] ), unchanged (nine studies [17, 22, [32] [33] [34] [35] [36] 38, 41, 43] ), or increased (one study [42] ).
Examining by procedure, the sole PN study and one of the RC studies reported equivalent ATRs in the ICS and control groups [17, 43] , with the remaining RC study reporting a significantly higher ATR in the ICS cohort [42] . In these three studies, the control group underwent no other blood conservation technique.
Studies differed substantially in their transfusion thresholds. The most common approach was holistic, with a joint surgeon-anaesthetist decision to transfuse, taking into account preoperative haemoglobin, patient comorbidities, estimated blood loss and vital signs [17, 32, 36, [39] [40] [41] [42] . Some used strict criteria of estimated blood loss or haemoglobin/ haematocrit level [22, [33] [34] [35] . Some studies had unclear or unstated allogeneic transfusion triggers [38, 41, 43] .
Radical Retropubic Prostatectomy Subgroup
No Blood Conservation Technique vs ICS
In four studies in patients undergoing RRP, ATRs were compared between ICS and no blood conservation technique groups [32, 34, 36, 39] . These data were suitable for metaanalysis, which found a significantly reduced odds ratio (OR) for allogeneic transfusion amongst patients in the ICS group of 0.34 (95% CI 0.15-0.76; Fig. 2 ).
Preoperative Autologous Donation vs ICS
Seven studies on RRP reported ATRs in ICS and PAD groups [22, [32] [33] [34] [35] 38, 41] . Meta-analysis found a non-significant trend towards a lower ATR amongst ICS groups, with an OR of 0.71 (95% CI 0.39-1.31; Fig. 2 ).
Oncological Outcomes
Ten studies reported oncological results (Table 1 and Appendix S5). None found ICS to be associated with worse outcomes. Compared with controls, patients in the ICS groups had equivalent outcomes in studies of patients undergoing RRP (six studies) [33, 34, 36, 37, 39, 40] , RC (one study) [42] or PN (one study) [43] . The blood conservation techniques available to controls were either PAD in two RRP studies [33, 34] or no technique [36, 37, 39, [41] [42] [43] . The remaining two titles reporting oncological data examined patients in the RRP group and found that, compared with PAD, the ICS cohort experienced superior outcomes [38, 41] .
There was significant inter-study variation in follow-up, recurrence determination method and reported oncological outcomes. Follow-up for ICS cohorts ranged from 7 to 61 months (median 32 months). This short follow-up is a major limitation of the data. Assessment of tumour recurrence after radical nephrectomy and RC was quite uniform, using clinical and radiological assessment in all three studies. By contrast, recurrence after RRP was variously determined by biochemical recurrence, defined as serum PSA >0.2 ng/L [34, 37, [39] [40] [41] , >0.4 ng/L [33, 36] , by the prescription of adjuvant therapies [33, 37] or per hospital registry [38] . Some studies used multiple definitions of recurrence.
Stated oncological outcomes included progression-free survival, disease-specific survival and biochemical recurrence.
Only four studies reported a survival analysis [33, 36, 40, 42] . These comprised studies on RRP, RC and PN, with comparators of PAD or no blood conservation technique. Given the variation in follow-up, methodology and reporting, meta-analysis was not possible. Oncological results for RRP studies that stated raw biochemical recurrence figures are presented in a forest plot, with the pooled estimate suppressed, in keeping with the Cochrane Handbook's guidance for heterogenous studies (Fig. 2 ) [26] .
Safety
Complications were reported by studies relating to RRP (one study) [32] , RC (two studies) [17, 42] and PN (one study) [43] . In all analyses, complications were not significantly different between groups. In the study by Chiusano et al. [32] , a three-way comparison of ICS, PAD and no blood conservation technique found no adverse events in any group. In the setting of RC or PN, complication rates for groups receiving ICS or no blood conservation technique were 39.5% vs 40.5% [42] and 21% vs 17% [43] , respectively. Lastly, Ubee et al. [17] reported non-cancer-related post-cystectomy perioperative mortality in both ICS (one death) and no blood conservation technique groups (two deaths).
Cost
We identified only three studies that examined the cost of ICS in urological surgery. In 1995, Gilbert et al. [22] found that, in managing RRP at their institution, pre-donating four units of autologous blood would be more economical than ICS and achieve similar allogeneic transfusion risk reduction (US$976 vs $1409 per patient ICS vs no blood conservation technique were £320 vs £675 and £163 vs £673, respectively.
Assessment of Bias
The Newcastle-Ottawa Scale suggested that risk of bias was low or moderate for 10 and four studies, respectively (Appendix S6). Most studies did not report ethics approval, conflicts of interest or funding information (Appendix S7). Similarly, the majority of studies excluded some patients, although in all cases the reviewers' deemed the reasoning appropriate. Two studies reported losses to follow-up, both representing <20% of the patient cohort.
Reporting bias may be present. This is particularly noticeable regarding complications, with one study stating intervention and comparator group adverse outcomes to be the 'same' without providing further data [17] , and another reporting only deaths [35] .
Funnel plots for each sub-set of RRP studies did not suggest publication bias, although these analyses were limited by the small number of studies (Fig. 3) . Publication bias was not assessable for the non-prostatectomy studies [39, 42, 43] .
Discussion
In the present review, we found low-level evidence that ICS reduces ATRs, most clearly when compared with no blood conservation technique for patients undergoing RRP. ICS appears safe, with no evidence of worse complications or recurrence. Data on cost were mixed, with newer studies suggesting cost savings with ICS.
These findings are consistent with several non-urological studies. The impact of ICS on ATR was assessed by two meta-analyses and a Cochrane Review. These found that, compared with no blood conservation technique, the relative risks of allogeneic transfusion for patients receiving ICS were significantly reduced at 0.59 (95% CI 0.48-0.73) [18] , 0.61 (95% CI 0.57-0.65) [44] and 0.62 (95% CI 0.55-0.70) [21] . In the present systematic review, studies reported a wide range of ATRs, often higher than those found in contemporary series also using the open approach [3] [4] [5] . This is important for two reasons. Firstly, the ATR heterogeneity influenced the meta-analyses, as ICS exerts most benefit when ATR is high. For example, in the quantitative analysis of RRP studies comparing ICS with no blood conservation technique ( Fig. 2A) , the control arm in the study by Ubee et al. [39] had an ATR of 72%, and so a large beneficial effect estimate was demonstrated when ICS was used. That study in 50 patients had far greater impact on the pooled estimate than did the study by Nieder et al. [36] who included >1 000 patients but had a much lower ATR of <2% in both groups. Secondly, the high reported ATRs may poorly correspond with modern experiences. Minimally invasive surgery, either laparoscopic or robot-assisted, is increasingly becoming the norm during prostatectomy, nephrectomy and, to a lesser extent, cystectomy, and is associated with a lower ATR. Transfusion rates will vary by procedure, surgical approach, patient population and surgeon, and the benefits of ICS will be reduced when the ATRs are lower; hence, health providers must examine averaged peri-operative transfusion indices for each of their major procedures to decide whether to use ICS. If published criteria are not met, such as estimated blood loss >20% of total blood volume, transfusion required in >10% of patients or mean transfusion exceeding 1 unit [45] , for that procedure health providers should consider selective rather than routine use of ICS.
The sole prior meta-analysis of cancer recurrence in ICS by Waters et al. [46] assessed 11 cohort studies, including five urological studies that were included in the present review [33, 34, [36] [37] [38] . Accepting inter-study heterogeneity, they found the pooled OR of cancer recurrence was lower for patients who underwent ICS (OR 0.65, 95% CI 0.43-0.98). This is consistent with the findings of the present review, with the 10 studies that reported recurrence data all demonstrating equivalent or superior oncological outcomes for patients in the ICS groups. Eight of these studies concern prostatectomy, but only one of these had a follow-up >5 years. Still greater uncertainty exists for recurrence after ICS use in nephrectomy or cystectomy. Only one study exists for each, both with small sample sizes and limited follow-up.
The ICS technique appeared not to affect complication rate, a finding supported by numerous non-urological studies. Large audits of ICS representing 18 000-64 000 units of salvaged blood have reported complication rates of <0.027%, which equates to one complication per 3 700 units reinfused [47, 48] . Similarly, a meta-analysis and a Cochrane review both found that complications rates were similar between ICS and other blood conservation techniques [18, 21] . A more recent metaanalysis of 47 RCTs found that, compared with allogeneic transfusion, ICS reduced the risk of postoperative infection (relative risk 0.72, 95% CI 0.54-0.97), with the risk of other complications unchanged [44] .
Cost benefit remains a source of controversy. Three urological studies were identified reporting cost data. The oldest found ICS to be more expensive than PAD [22] , while two more recent studies found ICS more economical than allogeneic transfusion alone [17, 39] . These latter results echo the sole meta-analysis of the economics of ICS, by Davies et al. [18] , which did not include urological studies. A wide range of blood conservation techniques were assessed, including erythropoietin, PAD, ANH, restrictive transfusion thresholds, fibrin sealants and antifibrinolytic drugs. ICS was found to be more cost-effective than all blood conservation techniques except ANH. With the cost of allogeneic transfusion high and increasing [45, 49] , the business case for ICS continues to strengthen; however, other non-urological Western studies have not found ICS to be economical [50] and experience in the developing world has, at best, demonstrated cost equivalence [50, 51] . A new ICS machine costs up to £4200, with disposables costs of £77 per use [39] . This may challenge under-resourced health systems, where 1 unit of screened donor blood commonly costs <US$50 [52] . Given inter-site variation in costs, transfusion requirements per procedure and healthcare models, ICS will not deliver savings for all users.
This is the first systematic review or meta-analysis of ICS in urology, and represents the highest English-language evidence to date on the topic. Twenty years ago, Jacobi et al. [53] published, in German, an RCT in 24 patients receiving RRP, with patients randomized to ICS or allogeneic transfusion.
Tumour recurrence data were not reported. This remains the sole urological RCT on ICS. Three reviews have previously covered sections of the urological ICS literature, but each has key weaknesses [46, 54, 55] . The review by Waters et al. [46] includes only five of the 14 studies identified in the present review, and does not separate studies by blood conservation technique during meta-analysis [46] . Kumar et al. [54] and Ferroni et al. [55] include seven and nine eligible urological studies, respectively; however, meta-analyses were not performed, and Kumar et al. erroneously included one non-ICS study. These reviews' findings echo our own, with ICS appearing to reduce ATR and cost, with unaltered rates of recurrence and complications.
Strengths of the present review are its robust methodology and comprehensive collation of relevant literature. Limitations include the lack of RCTs and the heterogenous methods of included studies. Potential biases are likely to be greater for non-randomized studies, so results should be interpreted with caution. Of particular concern is the potential for differences in the baseline characteristics of individuals in different groups (e.g. selection bias). This is the key difference between RCTs and non-randomized studies, and may have affected the present review, despite most studies stating some degree of statistical similarity between groups. While publication bias did not appear to be present, reporting bias did, with selected outcome reporting. Lack of information regarding ethical approval, funding and conflicts of interest were also common.
In conclusion, low-level evidence indicates that ICS use during uro-oncological surgery reduces both ATR and cost, and does not affect post-prostatectomy recurrence or complication rates. The small number of nephrectomy or cystectomy studies, all of small size and short follow-up, invalidate judgements on tumour recurrence after these procedures. Meta-analysis of the sub-group of RRP studies suggests that ICS reduces ATRs compared with no blood conservation technique but not compared with PAD. A preexisting meta-analysis of observational uro-oncological studies also found that ICS did not affect recurrence rates [46] . Prospective RCTs with long-term follow-up will enable greater certainty about the impact of ICS in urology.
